Navigation Links
Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
Date:9/11/2007

DOYLESTOWN, Pa., Sept. 11 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY) today issued an update on a Phase IIb Clinical Study of QR-333 on Diabetic Peripheral Neuropathy by its wholly owned subsidiary, Quigley Pharma, http://www.QuigleyPharma.com.

The update on the study noted that over 100 subjects have been enrolled, 52 subjects have completed treatment and over 225 subjects have been screened for the Phase IIB study designed to evaluate the safety and efficacy of the topical formulation on subjects with diabetic peripheral neuropathy. Subject screening and enrollment will continue to ensure a 140 evaluable patient study population. Once enrolled, subject treatment time is 12 weeks. To date the in-progress safety profile for this study has been consistent with the findings from the favorable safety results of the previous human proof of concept study conducted in France.

The screening process for enrollment is one of the most crucial aspects of a clinical drug trial, with only the most relevant subject population being selected, thus preventing a compromise of the resultant data and ensuring an accurate measure of the drugs evaluation. Consistent with other diabetic peripheral neuropathy studies, the inclusion/exclusion criteria for this trial are very stringent.

The subjects must:

-- be stable in their diabetes (reflective of their blood glucose levels)

-- have a confirmatory diagnosis of diabetic peripheral neuropathy with a

demonstrated level of pain (40 out of 100 on a visual analogue pain

scale) significant enough to be able to gauge an improvement

-- not have other serious diseases which would confound the data

-- not be on other medications which would confound the data

-- not so advanced in their neuropathy that they are not capable of

improvement

Although the Company believes enrollment should be completed before year end 2007, based on the protocol and stringent criteria submitted to the FDA, it is difficult to predict exactly when the study will be completed.

Currently in the United States, there are approximately 20,000,000 people with Diabetes. Of this population, nearly one half have or will have the symptoms of Peripheral Neuropathy. The company believes that a safe and effective topical product approved by the FDA as a "first line" treatment for diabetic peripheral neuropathy could develop a significant market position in a growing therapeutic category currently dominated by systemic therapies.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.


'/>"/>
SOURCE The Quigley Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Merge eMed releases software upgrade
11. Sony releases tool for Blu-ray disc production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... agreements with Nippon Shinyaku, Co., Ltd. for Defitelio ® ... daunorubicin liposome injection), or CPX-351, in Japan ... agreements, Nippon Shinyaku will receive exclusive rights to develop ... in return for an upfront payment to ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Crohn’s & Colitis ... inflammatory bowel diseases (IBD), and ReachMD , the nation’s largest medical education ... learners. , The partnership, which launched in the fall of 2016, includes ...
(Date:3/29/2017)... 29, 2017 "Surging application of gesture control ... government are expected to drive the growth of gesture ... recognition market is expected to be worth USD 18.98 ... between 2017 and 2022. The touchless sensing market is ... growing at a CAGR of 17.44% between 2017 and ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Nerium International Mexico has been approved as an active member of the ... and protection among distributers and consumers in relationship marketing. This professional organization fosters ...
Breaking Biology Technology:
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
Breaking Biology News(10 mins):